Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,827 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Supraclavicular recurrence after early breast cancer: a curable condition?
Pedersen AN, Møller S, Steffensen KD, Haahr V, Jensen M, Kempel MM, Jepsen SL, Madsen EL, Roslind A, Sandberg E, Schöllkopf C, Sørensen PG, Windfeldt KM, Andersson M. Pedersen AN, et al. Among authors: andersson m. Breast Cancer Res Treat. 2011 Feb;125(3):815-22. doi: 10.1007/s10549-010-0918-8. Epub 2010 May 8. Breast Cancer Res Treat. 2011. PMID: 20454924
The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial.
de Azambuja E, McCaskill-Stevens W, Francis P, Quinaux E, Crown JP, Vicente M, Giuliani R, Nordenskjöld B, Gutiérez J, Andersson M, Vila MM, Jakesz R, Demol J, Dewar J, Santoro A, Lluch A, Olsen S, Gelber RD, Di Leo A, Piccart-Gebhart M. de Azambuja E, et al. Among authors: andersson m. Breast Cancer Res Treat. 2010 Jan;119(1):145-53. doi: 10.1007/s10549-009-0512-0. Breast Cancer Res Treat. 2010. PMID: 19731015 Clinical Trial.
Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer.
Reding KW, Bernstein JL, Langholz BM, Bernstein L, Haile RW, Begg CB, Lynch CF, Concannon P, Borg A, Teraoka SN, Törngren T, Diep A, Xue S, Bertelsen L, Liang X, Reiner AS, Capanu M, Malone KE; WECARE Collaborative Study Group. Reding KW, et al. Breast Cancer Res Treat. 2010 Sep;123(2):491-8. doi: 10.1007/s10549-010-0769-3. Epub 2010 Feb 5. Breast Cancer Res Treat. 2010. PMID: 20135344 Free PMC article.
Antiangiogenic therapy for breast cancer.
Nielsen DL, Andersson M, Andersen JL, Kamby C. Nielsen DL, et al. Among authors: andersson m. Breast Cancer Res. 2010;12(5):209. doi: 10.1186/bcr2642. Epub 2010 Sep 29. Breast Cancer Res. 2010. PMID: 21067536 Free PMC article. Review.
Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study.
Andersson M, Lidbrink E, Bjerre K, Wist E, Enevoldsen K, Jensen AB, Karlsson P, Tange UB, Sørensen PG, Møller S, Bergh J, Langkjer ST. Andersson M, et al. J Clin Oncol. 2011 Jan 20;29(3):264-71. doi: 10.1200/JCO.2010.30.8213. Epub 2010 Dec 13. J Clin Oncol. 2011. PMID: 21149659 Clinical Trial.
2,827 results